echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovative topical drug for the treatment of presbyopia reaches phase 3 clinical endpoint

    Innovative topical drug for the treatment of presbyopia reaches phase 3 clinical endpoint

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Eyenovia today announced that its proprietary pilocarpine formula MicroLine has reached the primary endpoint in the Phase 3 clinical trial VISION-1 for the treatment of presbyopia patients, significantly improving the near vision of adult patients with presbyopia.


    Presbyopia is an age-related progressive hardening of the lens of the eye, making it difficult for the transparent lens of the eye to change shape.


    The VISION-1 study evaluated the safety and effectiveness of Eyenovia's 1% and 2% pilocarpine formulations MicroLine compared with placebo.


    VISION-1 reached its primary endpoint.


    At the same time, MicroLine was well tolerated, with all adverse events being mild and no serious adverse events.


    Note: The original text has been deleted

    Reference materials:

    [1] Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.